SCHEMBL3740259

SCHEMBL3740259

Fc1cc(-c2nc(N3C[CH]CCC3)c3sccc3n2)c(F)cc1Cl

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 1/20 0.38
PDE4B Q07343 1/20 0.38
PDE4C Q08493 1/20 0.38
PDE4D Q08499 1/20 0.38
PDE3B Q13370 1/20 0.38
PDE3A Q14432 1/20 0.38
PIK3CA P42336 11/20 0.38
MTOR P42345 8/20 0.38
PIK3C2B O00750 1/20 0.36
CCNE2 O96020 1/20 0.36
PRKACA P17612 1/20 0.36
PRKACG P22612 1/20 0.36
PRKACB P22694 1/20 0.36
CCNE1 P24864 1/20 0.36
CDK2 P24941 1/20 0.36
KDR P35968 1/20 0.36
PIK3CB P42338 1/20 0.36
PIK3CG P48736 1/20 0.36
PRKCI P41743 2/20 0.36
PIK3R1 P27986 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL391776 0.88 PDE4A (0.44) PDE4APDE4BPDE4CPDE4DPDE3B
Hydrochloric Acid SCHEMBL4518915 0.87 PDE4A (0.43) PDE4APDE4BPDE4CPDE4DPDE3B
SCHEMBL4517579 0.85 PIK3CA (0.43) PDE4APDE4BPDE4CPDE4DPDE3B
SCHEMBL5052071 0.83 PIK3CA (0.38) PDE4APDE4BPDE4CPDE4DPDE3B
SCHEMBL389433 0.82 HTR2C (0.50) PIK3CAMTORPIK3C2BCCNE2PRKACA
SCHEMBL4518887 0.82 PIK3CA (0.39) PDE4APDE4BPDE4CPDE4DPDE3B
SCHEMBL388490 0.81 PIK3CA (0.41) PDE4APDE4BPDE4CPDE4DPDE3B
Hydrochloric Acid SCHEMBL4519773 0.81 HTR2C (0.49) PIK3CAMTORPIK3C2BCCNE2PRKACA
SCHEMBL388188 0.81 PRKCI (0.40) PDE4APDE4BPDE4CPDE4DPDE3B
Hydrochloric Acid SCHEMBL4508396 0.80 PIK3CA (0.41) PDE4APDE4BPDE4CPDE4DPDE3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2253311-A2 Use of GPR119 receptor agonists for increasing bone mass and for treating osteoporosis, as well as combination therapy relating thereto Arena Pharmaceuticals, Inc. (US) 2010-11-24 EP disclosed
EP-1806347-A1 AROMATIC-RING-FUSED PYRIMIDINE DERIVATIVE Astellas Pharma Inc. (JP) 2007-07-11 EP disclosed